DEX-M74 for GNE Myopathy
DEX-M74 for GNE Myopathy
批准号:
9205573
负责人:
Na Yang
金额:
$200.38万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
中文摘要
GNOE肌病是一种罕见的成人起病的肌肉疾病,以进行性肌肉无力为特征,发病后10至20年内导致严重丧失工作能力。GNE肌病是一种遗传性疾病,可追溯到GNE基因的突变。GNOE编码一种酶,催化唾液酸(SA)生物合成的前两步。随后SA产生的不足被认为是导致肌肉糖蛋白唾液酸化减少,导致肌肉退化的原因。
最近的研究表明,SA前体N-乙酰-D-甘露糖胺(ManNAc,或DEX-M74)可能成为治疗GNE肌病的药物。美国国立卫生研究院(NIH)的国家人类基因组研究所就ManNAc用于治疗GNE肌病提交了专利申请,并于2007年向美国食品和药物管理局(FDA)提交了研究性新药(IND)申请,以进行I/II期临床试验,测试ManNAc在GNE肌病患者中的安全性和有效性。FDA发布了暂停这项临床试验的通知,理由是需要进行额外的临床前研究。
TRND支持完成了两项关键的动物毒理学研究,并生成了生产最终药物产品所需的制造工艺数据。这项工作使TRND完成了IND申请申请,以获得FDA的批准,解除了阻止启动人体试验的临床搁置。为了收集临床试验所需的疾病信息,TRND的科学家们在2011年开始了一项关于GNE肌病疾病进展的自然历史研究。在FDA批准后,NIH临床中心启动了针对GNE肌病患者的I期临床研究。这项研究已经结束,第二阶段临床试验正在进行中。
英文摘要
GNE myopathy is a rare adult-onset muscular disorder characterized by progressive muscle weakness, resulting in severe incapacitation within 10 to 20 years after onset. GNE myopathy is a genetic disorder that has been traced to mutations in the GNE gene. GNE encodes an enzyme that catalyzes the first two steps in the biosynthesis of sialic acid (SA). The subsequent deficiency of SA production is presumed to cause decreased sialylation of muscle glycoproteins, resulting in muscle degeneration.
Recent studies have implicated the SA precursor N-acetyl-D-mannosamine (ManNAc, or DEX-M74) as a potential therapeutic agent for the treatment of GNE myopathy. The National Human Genome Research Institute at the National Institutes of Health (NIH) filed a patent application on the use of ManNAc for the treatment of GNE myopathy, and filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) in 2007 to conduct a Phase I/II clinical trial testing the safety and efficacy of ManNAc in GNE myopathy patients. The FDA issued a hold on this clinical trial, citing the need for additional pre-clinical studies.
TRND supported the completion of two pivotal animal toxicology studies and generated required data on the manufacturing processes to produce the final drug product. This work allowed TRND to complete the IND Application filing to gain FDA approval to lift the clinical hold preventing initiation of human trials. To gather the information on the disease required for a clinical trial, TRND scientists began a natural history study of GNE myopathy disease progression in 2011. After clearance from the FDA, a Phase I clinical study was initiated in GNE myopathy patients at the NIH Clinical Center. This study has concluded, and a Phase II clinical trial is now underway.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Long-Acting Parathyroid Hormone Analog for the Treatment of Hypoparathyroidism
-
批准号:9354957
-
项目类别:
-
资助金额:$176.51万
-
财政年份:--
-
负责人:Na Yang
-
依托单位:
Long-Acting Parathyroid Hormone Analog for the Treatment of Hypoparathyroidism
-
批准号:9551298
-
项目类别:
-
资助金额:$245.31万
-
财政年份:--
-
负责人:Na Yang
-
依托单位:
Long-Acting Parathyroid Hormone Analog for the Treatment of Hypoparathyroidism
-
批准号:9205575
-
项目类别:
-
资助金额:$200.38万
-
财政年份:--
-
负责人:Na Yang
-
依托单位:
Gene Therapy Platform for Rare Diseases
-
批准号:9551937
-
项目类别:
-
资助金额:$205.31万
-
财政年份:--
-
负责人:Na Yang
-
依托单位:
Gene Therapy Platform for Rare Diseases
-
批准号:10004998
-
项目类别:
-
资助金额:$322.87万
-
财政年份:--
-
负责人:Na Yang
-
依托单位:
海外基金